Assembly Biosciences
Dr. Zoulim is Professor of Medicine at Lyon University since 1997. He is Head of the Hepatology Department at the Hospices Civils de Lyon, and Head of the Viral Hepatitis Research Laboratory of INSERM Unit 1052. Dr. Zoulim has served as an Associate Editor for Journal of Hepatology and is currently Associate Editor for Gut. He also served as an expert in the microbiology study section of the INSERM, as head of the clinical viral hepatitis study section at National Agency for Research on AIDS and Viral Hepatitis (ANRS), and as a Governing Board member of the European Association for the Study of the Liver (EASL). Dr Zoulim received the William Prusoff award of the International Society for Antiviral Research. He has been the scientific coordinator of an EU-funded Network of Excellence on the management of antiviral drug resistance. He is currently coordinating the ANRS “HBV cure” program in France and the “IP-cure-B” project within the EU H2020 workprogram and co-founded the International Coalition to Eliminate HBV. Dr. Zoulim is a recognized expert in the field of viral hepatitis and antiviral therapy and has published more than 400 articles. He earned his MD in Gastroenterology and Hepatology in Lyon Medical School in 1991. Dr. Zoulim also earned a PhD in Molecular and Cellular Biology and was trained as a post-doctoral researcher at Fox Chase Cancer Center in Philadelphia.
This person is not in the org chart
This person is not in any offices
Assembly Biosciences
9 followers
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.